Literature DB >> 28159024

Excess long-term mortality among hospital survivors of acute myocardial infarction. Soroka Acute Myocardial Infarction (SAMI) project.

Y Plakht1, H Gilutz2, A Shiyovich3.   

Abstract

OBJECTIVES: We evaluated long-term survival after acute myocardial infarction (AMI) in unselected 'real life' patients according to the various risk groups, and it's persistence with time after AMI as compared with the matched general population. STUDY
DESIGN: Retrospective study.
METHODS: Data were collected from 2671 AMI hospital survivors (tertiary medical centre in Israel), which included demographics, clinical characteristics of AMI, comorbidities, interventions and test results. All-cause mortality during the 10-year follow-up period was compared with age-, sex- and ethnicity/religion-matched general population using standardized mortality ratios (SMRs).
RESULTS: Overall mortality of AMI patients (48.6%) was higher than the general population (SMR, 2.2; P < 0.001). Mortality rates and SMRs tended to be greater in higher risk strata of patients, Jews vs Muslims, women vs men, non-ST-elevation acute myocardial infarction (NSTEMI) vs ST-elevation acute myocardial infarction (STEMI), non-invasive treatment vs invasive treatment, and recurrent vs first AMI. Mortality rates increased with age, but SMRs were highest in the youngest group. Through the follow-up period, SMR was highest during the first year after discharge (SMR, 4.85; P < 0.001) and higher in 7th-10th years compared with 2nd-6th years.
CONCLUSION: Patients who survived hospital admission with AMI continue to be at higher (approximately twice) risk of death compared with the general population for at least 10-year follow-up period and especially throughout the first and 7th-10th years after AMI, young women, high-risk patients, Jews, NSTEMI, non-invasively treated and recurrent AMI. These findings can assist healthcare providers and decision makers prioritizing targets of secondary prevention and allocation of resources.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Acute myocardial infarction; All-cause mortality; General population; Prognosis

Mesh:

Year:  2016        PMID: 28159024     DOI: 10.1016/j.puhe.2016.09.032

Source DB:  PubMed          Journal:  Public Health        ISSN: 0033-3506            Impact factor:   2.427


  6 in total

1.  Long-term Survival After Out-of-Hospital Cardiac Arrest: A Systematic Review and Meta-analysis.

Authors:  Simon A Amacher; Chantal Bohren; René Blatter; Christoph Becker; Katharina Beck; Jonas Mueller; Nina Loretz; Sebastian Gross; Kai Tisljar; Raoul Sutter; Christian Appenzeller-Herzog; Stephan Marsch; Sabina Hunziker
Journal:  JAMA Cardiol       Date:  2022-06-01       Impact factor: 30.154

2.  Protective effect of morin on myocardial ischemia‑reperfusion injury in rats.

Authors:  Shuang Liu; Nan Wu; Jiaxin Miao; Zijun Huang; Xuying Li; Pengyu Jia; Yuxuan Guo; Dalin Jia
Journal:  Int J Mol Med       Date:  2018-06-26       Impact factor: 4.101

3.  Is depression a real risk factor for acute myocardial infarction mortality? A retrospective cohort study.

Authors:  Silvia Cocchio; Tatjana Baldovin; Patrizia Furlan; Alessandra Buja; Patrizia Casale; Marco Fonzo; Vincenzo Baldo; Chiara Bertoncello
Journal:  BMC Psychiatry       Date:  2019-04-24       Impact factor: 3.630

4.  Treatment with metformin prevents myocardial ischemia-reperfusion injury via STEAP4 signaling pathway.

Authors:  Ting Luo; Xianli Zeng; Wenqi Yang; Yuelan Zhang
Journal:  Anatol J Cardiol       Date:  2019-04       Impact factor: 1.596

5.  Monocyte/lymphocyte ratio is related to the severity of coronary artery disease and clinical outcome in patients with non-ST-elevation myocardial infarction.

Authors:  Hui Chen; Min Li; Lei Liu; Xiawei Dang; Danjun Zhu; Gang Tian
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

6.  Temporal trends in healthcare resource utilization and costs following acute myocardial infarction.

Authors:  Arthur Shiyovich; Harel Gilutz; Jonathan Eli Arbelle; Dan Greenberg; Ygal Plakht
Journal:  Isr J Health Policy Res       Date:  2020-02-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.